2024
Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin
Lomakin I, Devarkar S, Grada A, Bunick C. Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024, 144: 2553-2561.e3. PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.Peer-Reviewed Original ResearchNetwork of water-mediated interactionsCutibacterium acnesPeptide bond formationNascent peptideWater-mediated interactionsTranslational inhibitionAntibiotic resistanceCryogenic electron microscopyA-resolutionMechanistic basesAntibiotic-based therapiesRRNAAminoacyl groupRibosomeAcne pathogenesisAcne therapyAntibiotic stewardshipClindamycinIncreased resistanceAcne vulgarisClinical targetsAcneAntibioticsPeptideTRNAClindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.
Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.Peer-Reviewed Original ResearchAcne vulgarisTreatment of acne vulgarisApplication of clindamycinCutaneous bacterial infectionsAntibiotic treatment efficacyTopical clindamycinTopical agentsOral treatmentClindamycinSystemic agentsMultiple disease statesPharmacokinetic profileTreatment efficacyAntibiotic resistanceBacterial infectionsAntibiotic mechanismsTherapeutic valueRelevance to cliniciansDisease statesDermatologyLincosamide antibioticsAnti-inflammatoryGram-positiveAnaerobic bacteriaAcneScientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.Peer-Reviewed Original ResearchSoft tissue infectionsTetracycline class antibioticsTreatment of dermatological diseasesMechanism of protein synthesis inhibitionClindamycin useStaphylococcal infectionsTissue infectionsClinical presentationAnti-inflammatory propertiesHidradenitis suppurativaEffective antibioticsTreatment optionsClindamycinClinical evidenceAcne vulgarisClinical basisProtein synthesis inhibitionDermatological indicationsAmeliorate inflammationAntibiotic resistanceDermatology practiceBacterial ribosomeDermatological diseasesClass antibioticsLesion formationAvoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations
Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s355. DOI: 10.25251/skin.8.supp.355.Peer-Reviewed Original ResearchCombination of clindamycinC. acnes strainsMinimum inhibitory concentrationCutibacterium acnesCombination of benzoyl peroxideExposure to antibioticsConcentrations of clindamycinEpsilometer testBacterial cultureDevelopment of resistanceFixed combinationMeasuring zones of inhibitionAntibiotic susceptibilityCheckerboard assayClinical strainsClindamycinAntibiotic formulationsC. acnesAntibiotic resistanceProlonged useAntibioticsZone of inhibitionAgar diffusion methodInhibitory concentrationCombination formulationAvoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations
Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s354. DOI: 10.25251/skin.8.supp.354.Peer-Reviewed Original ResearchCombination of clindamycinC. acnes strainsMinimum inhibitory concentrationCutibacterium acnesCombination of benzoyl peroxideExposure to antibioticsConcentrations of clindamycinEpsilometer testBacterial cultureDevelopment of resistanceFixed combinationMeasuring zones of inhibitionAntibiotic susceptibilityCheckerboard assayClinical strainsClindamycinAntibiotic formulationsC. acnesAntibiotic resistanceProlonged useAntibioticsZone of inhibitionAgar diffusion methodInhibitory concentrationCombination formulation
2023
Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.
Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.Peer-Reviewed Original ResearchConceptsOral antibiotic useOral antibioticsAntibiotic useAntibiotic treatmentAcne treatmentHealth care claims dataOral antibiotic treatmentShort study durationIBM MarketScanPrimary outcomeGuideline recommendationsRetrospective studyAcne vulgarisRetrospective analysisClaims dataJ DrugsPatientsStudy durationAmerican AcademyTherapeutic classesSeparate occasionsDay gapMonthsAntibiotic resistanceAntibiotics
2022
Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris
Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.Peer-Reviewed Original ResearchAcne vulgarisSevere acne vulgarisAntibiotic resistancePotential side effectsOral tetracyclineGut dysbiosisPatients 9Gastrointestinal upsetRisk of resistanceSide effectsDrug AdministrationTetracycline treatmentSarecyclineTetracycline usageAcneTreatmentTetracyclineAntibiotic resistance riskPathogenic bacteriumRiskVulgarisDizzinessVertigoDysbiosisMinocyclineSarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology
Grada A, Ghannoum MA, Bunick CG. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics 2022, 11: 722. PMID: 35740129, PMCID: PMC9220064, DOI: 10.3390/antibiotics11060722.Peer-Reviewed Original ResearchBroad-spectrum tetracyclineInflammatory dermatosesAntibiotic stewardshipStaphylococcal infectionsClinical effectivenessSkin diseasesCutaneous staphylococcal infectionsReported adverse eventsFirst-line agentsInflammatory skin diseaseMucous membrane pemphigoidAnti-inflammatory propertiesStaphylococcal skin infectionsAntibiotic resistanceTetracycline-class antibioticsAdverse eventsAcne rosaceaClinical findingsCutaneous infectionsAcne vulgarisSkin infectionsMedicine careStrong rationaleInfectionMultiple skin diseases
2021
Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation
Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.Peer-Reviewed Original ResearchTetracycline-class antibioticsBroad-spectrum antibiotic useRat paw edema modelPaw edema modelAnti-inflammatory activityWound infection modelSevere acneEdema modelPatient outcomesAntibiotic useMurine modelAnimal modelsDrug AdministrationGut microfloraInfection modelSarecyclineVivo studiesRelevant Gram-positive bacteriaReduced efficacyInfectionAntimicrobial resistanceVivo activityAntibiotic resistanceInflammationReduced activity